Clinical trial · Interventional
[18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy
Study of the Kinetics, Dosimetry and Safety of [18F]F-AraG (VisAcT), a Positron Emission Tomography Tracer for Imaging the Activation of the Immune System in Cancer Patients Who Have Received or Are Expected to Receive Immunotherapy and/or Radiation Therapy
NCT03142204CI-TRIAL-00062483unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a Phase 1 study is to visualize biodistribution of a PET tracer called \[18F\]F-AraG (VisAcT) in cancer patients expected to undergo immunotherapy and/or radiation therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [18F]F-AraG | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Visualize biodistribution of the PET tracer [18F]F-AraG pre-immunotherapy
- timeFrame
- Up to 6 weeks before immunotherapy is administered
- description
- Whole-body \[18F\]F-AraG PET scan will be performed after intravenous injection of the PET tracer.consecutive time points the day of the intravenous injection of the PET tracer.
- measure
- Visualize biodistribution of the PET tracer [18F]F-AraG post start of immunotherapy
- timeFrame
- Up to 12 weeks after start of immunotherapy
- description
- Whole-body \[18F\]F-AraG PET scan will be performed after intravenous injection of the PET tracer.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Cancer patients with identified tumor mass * Cancer patients expected to undergo immunotherapy and/or radiation therapy Exclusion Criteria: * Under the age of 18 * Pregnant women * Women who are breastfeeding * Individuals with known or suspected substance abuse * Individuals unable or unwilling to comply with the study procedures
References
Publications (0)
Data not yet available
No reference posted for this study.